AILERON THERAPEUTICS, INC.
281 Albany Street
Cambridge, MA 02139
June 26, 2017
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Aileron Therapeutics, Inc. |
| Registration Statement on Form S-1 |
| File No. 333-218474 |
| Request for Acceleration |
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Aileron Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-218474), as amended (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on June 28, 2017, or as soon thereafter as practicable.
* * * *
| Very truly yours, | ||
| AILERON THERAPEUTICS, INC. | ||
| By: | /s/ Joseph A. Yanchik III | |
| Name: | Joseph A. Yanchik III | |
| Title: | President and Chief Executive Officer | |
| cc: | Stuart M. Falber, Wilmer Cutler Pickering Hale and Dorr LLP |
| Joshua D. Fox, Wilmer Cutler Pickering Hale and Dorr LLP |
| Peter N. Handrinos, Latham & Watkins LLP |